By Fineline Cube 
China-based Ab&B Bio-Tech CO., LTD. JS (HKG: 2627) announced that its self-developed investigational new drug application (IND) for the recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) (adjuvanted) has been approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. Additionally, the vaccine’s IND application has also been approved by the U.S. Food and Drug Administration (FDA).
Vaccine Development
Ab&B’s recombinant RSV vaccine (CHO cell) (adjuvanted) was developed using CHO cells and is designed to express a modified pre-F protein. Preclinical studies have demonstrated its higher pre-F expression levels, better thermal stability, and superior immunogenicity compared to existing approved vaccines.
Target Population
Respiratory syncytial virus (RSV) is a highly contagious RNA virus and a leading cause of respiratory infections in infants, the elderly, and immunocompromised individuals. The vaccine aims to provide protection against this significant health threat.-Fineline Info & Tech